vidarabine has been researched along with Carcinoma, Basal Cell, Pigmented in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Streu, E | 1 |
| Hirschman, R; Mastan, A; Ng, R; Rashid, K; Sager, D | 1 |
2 other study(ies) available for vidarabine and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Second malignancies in chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chlorambucil; Combined Modality Therapy; Ear Neoplasms; Early Diagnosis; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasms, Second Primary; Risk; Rituximab; Skin; Skin Neoplasms; Vidarabine | 2014 |
Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |